Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health & Wellness Today New York.
Press releases published on July 24, 2025
Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewswire
·
July 24, 2025
MENLO PARK, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and …
CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025
GlobeNewswire
·
July 24, 2025
Company to share primary endpoint results at 32-Weeks from Extension phase following late-breaking presentations at Alzheimer's Association International Conference® (AAIC) 2025 Conference call and webcast to be held Monday, July 28 at 8:00 AM ET BOSTON, …
Treace to Report Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewswire
·
July 24, 2025
PONTE VEDRA, Fla., July 24, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities …
RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewswire
·
July 24, 2025
ALISO VIEJO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the …
OPKO Health to Report Second Quarter 2025 Financial Results on July 31
GlobeNewswire
·
July 24, 2025
MIAMI, July 24, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on Thursday, July 31, 2025. OPKO’s …
Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewswire
·
July 24, 2025
HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, …
Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025
GlobeNewswire
·
July 24, 2025
LONDON, July 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 29, 2025 at 8:30 a.m. Eastern Time to report its second quarter 2025 …
Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer
GlobeNewswire
·
July 24, 2025
MINNEAPOLIS, July 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the first patient has been dosed in VIKTORIA-2, its Phase 3 …
Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq
GlobeNewswire
·
July 24, 2025
- Special Meeting of Stockholders to be Held Virtually on September 5, 2025 - - Live Stockholder Fireside Chat to be Scheduled to Answer Frequently Asked Stockholder Questions - - Nasdaq Hearings Panel Meeting Scheduled on August 14, 2025 - SOUTH SAN …
Cytokinetics to Announce Second Quarter Results On August 7, 2025
GlobeNewswire
·
July 24, 2025
SOUTH SAN FRANCISCO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 7, 2025 at 4:00 PM Eastern Time. Following the announcement, …
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
GlobeNewswire
·
July 24, 2025
REDWOOD CITY, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of a peer- …
Merakris Therapeutics Spotlights Investigational New Drug, MTX-001, with Innovation Showcase Win at 2025 Advanced Wound Care Summit
GlobeNewswire
·
July 24, 2025
RESEARCH TRIANGLE PARK, N.C., July 24, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces it was selected as the winner of the 2025 Innovation Showcase at the Advanced Wound Care (AWC) Summit held last week in Boston. The award recognizes the most …
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
GlobeNewswire
·
July 24, 2025
Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2 …
Approbation de Cabometyx® dans l’UE pour les tumeurs neuroendocrines avancées précédemment traitées
GlobeNewswire
·
July 24, 2025
Cabometyx® est le premier et unique traitement systémique autorisé dans l’Union européenne pour les tumeurs neuroendocrines non résécables ou métastatiques précédemment traitées, indépendamment de la localisation de la tumeur, de sa gravité et de l’ …
Global Digital Biopsy Market Poised for Extraordinary Growth at a CAGR of ~17% by 2032 | DelveInsight
GlobeNewswire
·
July 24, 2025
New York, USA, July 24, 2025 (GLOBE NEWSWIRE) -- Global Digital Biopsy Market Poised for Extraordinary Growth at a CAGR of ~17% by 2032 | DelveInsight Global demand for digital biopsy is on the rise, fueled by the growing prevalence of cancers such as …
Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight
GlobeNewswire
·
July 24, 2025
New York, USA, July 24, 2025 (GLOBE NEWSWIRE) -- Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight The non-Hodgkin’s lymphoma market size is expected to increase during the forecast …
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ESMO Congress 2025
GlobeNewswire
·
July 24, 2025
SEATTLE, July 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that updated …
Fairhaven Health Strengthens Women’s Health Commitment Beyond Fertility
GlobeNewswire
·
July 24, 2025
MIDDLETOWN, Conn., July 24, 2025 (GLOBE NEWSWIRE) -- As the world honors World IVF Day, Fairhaven Health — a company long recognized by reproductive health professionals for its fertility-focused supplements — is reaffirming its commitment to evidence- …
Omniscient and The Jacobs Institute, Inc. Announce Strategic Partnership to Pioneer Clinical Connectomics
GlobeNewswire
·
July 24, 2025
BUFFALO, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Omniscient (o8t®), the global leader in connectomics, is proud to announce a groundbreaking partnership with The Jacobs Institute, Inc. (JI), a one-of-a-kind non-profit medical device innovation center. This …
Guerbet : H1 2025 revenue
GlobeNewswire
·
July 24, 2025
H1 2025 revenue First-half activity H1 revenue of €387.8 million, down 5.4% at CER1 and like-for-like2 largely due to the fall in activity in France Sales at CER and on a like-for-like basis increased in EMEA excluding France (+6.9%), were stable in the …